

1 **Clinical Practice Guideline:** **Practice Parameters and Review Criteria**

2  
3 **Date of Implementation:** **April 24, 2003**

4  
5 **Product:** **Specialty**

6  
7  
8 **Development**

9 American Specialty Health - Specialty (ASH) is charged, through its role as a health plan,  
10 to ensure that practitioners comply with professionally recognized standards of practice  
11 and established diagnostic and treatment planning practices acceptable to ASH's clinical  
12 committees. ASH develops practice parameters and review criteria by evaluating  
13 professionally recognized standards of practice and existing practice parameters. These  
14 practice parameters and review criteria serve as decision-assist tools by which  
15 practitioners are evaluated during the credentialing, clinical services management,  
16 clinical performance management, and recredentialing processes.

17  
18 ASH defines professionally recognized standards of practice as those based on peer-  
19 reviewed, published research data and the educational standards accepted by the majority  
20 of the profession's educational institutions. Practices and protocols that are incorporated  
21 into baseline education, competency training, and certification or licensure testing  
22 requirements of the profession's regulators (e.g., national and state boards and/or  
23 certifying entities) are also considered contributory to professionally recognized  
24 standards of practice. The evaluation of this information will result in the identification  
25 and definition of professionally recognized standards of practice in terms of safety,  
26 efficiency, clinical rationale, reproducibility, reliability, and an understanding of the  
27 rationale behind why practices and procedures are utilized.

28  
29 These standards produce reasonable, reliable, and expected functional outcomes of the  
30 clinical encounter, thus guiding the practitioner and maximizing the clinical benefit to the  
31 member. These standards also identify known risks, methods to minimize those risks, and  
32 methods to manage adverse outcomes should they occur.

33  
34 Practice parameters and review criteria have been developed from review of scientific  
35 literature (see policy Selected List of References - CPG 5 – S), consensus of ASH clinical  
36 peer review committees comprised of contracted practitioners, and expert opinion. The  
37 purpose of developing practice parameters and review criteria is to provide clinicians and  
38 clinical quality evaluators, respectively, a consistent and reliable method of evaluating  
39 diagnostic and therapeutic rationale. These practice parameters and review criteria are  
40 evaluated at least annually, and may be modified at any time. The Evidence Evaluation  
41 Committee (EEC) reviews the published literature related to specific clinical practices,  
42 and evaluates the validity and reliability of the clinical practice. Additionally, the

1 Professional Affairs Healthcare Advisory Committee (PAHAC) may provide input  
 2 regarding what is taught in the professional schools and/or broadly accepted and  
 3 commonly practiced. See policy Technology Assessment - QM 4 - S for additional  
 4 information regarding how EEC, PAHAC, the Clinical Quality Team (CQT), and the  
 5 Quality Improvement Committee (QIC) - consisting of contracted practitioners - develop  
 6 clinical policy. Clinical policy is then reviewed by the Quality Oversight Committee  
 7 (QOC) on behalf of the Board of Directors (BOD) prior to implementation.

8  
 9 ASH practice parameters and review criteria should:

- 10 • Be relevant to clinical practices that ASH members may encounter in a  
 11 practitioner’s office;
- 12 • Be rigorous in defense of optimal “best-clinical practice;”<sup>1</sup>
- 13 • Consider current optimal best-clinical practice as compared to current common  
 14 practice; and
- 15 • Be consistent with the procedures and processes defined within the credentialing,  
 16 clinical performance management, and clinical services management programs.

17  
 18 Further, the use of these practice parameters should provide acceptable, scientifically  
 19 valid, professionally ethical, and responsible support for the decisions made in the  
 20 management of clinical services rendered to members.

21  
 22 Considerations in the development of these practice parameters and review criteria  
 23 include:

- 24 • The practitioner is professionally and ethically responsible for delivering  
 25 optimally efficient and effective care;
- 26 • The practitioner is obligated to the member to establish mutually agreed upon and  
 27 measurable outcomes of care;
- 28 • The practitioner renders services for the sole purpose of substantiating a  
 29 diagnosis, developing a member-specific treatment plan/program, and/or treating  
 30 a member’s illness or injury;
- 31 • The purpose of treatment is to restore the member’s functional health status or  
 32 stabilize a chronic condition.
- 33 • ASH is responsible for supporting clinically safe and effective complementary  
 34 health care in conjunction with its practitioners;

---

<sup>1</sup> “Best-clinical practice”: An optimal best-clinical practice is a procedure or protocol that is most likely to be utilized by a majority of credentialed peers for the purpose it is being applied, is accepted by the profession’s academic institutions to the point of being a component of the core curriculum, is tested to competency by accepted academic institutions and regulatory bodies or agencies, and is the procedure or practice most likely to result in favorable clinical outcomes for the patient/client for which this service may be used.

- 1 • ASH is responsible for meeting its members’ healthcare needs within the limits of
- 2 the member’s applicable benefit plan;
- 3 • ASH has a clinical responsibility to verify as medically necessary only those
- 4 services that are optimal, efficient, and meet professionally accepted standards of
- 5 care;
- 6 • ASH recognizes that treatment or diagnostic procedures outside of professional
- 7 standards may delay effective care and lead to member harm.

8  
 9 Health care services covered by ASH must be consistent with ASH Clinical Practice  
 10 Guidelines and other related policies, are scientifically valid and published in broadly  
 11 accepted, professional peer-reviewed clinical literature to be safe (defined below),  
 12 effective (likely to result in expected favorable outcome), and reliable (likely to result in  
 13 a known outcome each time the procedure is applied).

14  
 15 Evidence-based criteria is defined as those documented clinical concepts, rules, practices,  
 16 procedures, outcomes, and rationale approved by ASH’s clinical committees and QOC,  
 17 and includes the following:

- 18 • Supported by valid scientific documented evidence (1) or approved by ASH peer-
- 19 consensus evidence (2) if valid scientific documented evidence of diagnostic or
- 20 therapeutic reliability and reproducibility is non-existent;
- 21 • Known to be physiologically effective and/or based on accepted physiological
- 22 knowledge (not experimental/investigational);
- 23 • Safe/low risk (3);
- 24 • Based on clinical evidence (4).

25  
 26 (1) Documented evidence:

27 ASH accepts for review evidence that has been published in clinical literature and  
 28 peer-reviewed by an acceptable representative segment of the profession.  
 29 Documented evidence is demonstrated by independent validity, reliability, and  
 30 reproducibility, and is derived by accepted scientific methods. Documented evidence  
 31 may also include valid case studies. Anecdotal opinion is not considered valid  
 32 documented evidence.

33  
 34 (2) Consensus evidence:

35 Consensus evidence may be accepted as standard of practice by ASH when  
 36 scientifically valid peer-documented evidence is non-existent. Consensus evidence is  
 37 developed through an ASH accepted peer review process that elicits majority  
 38 consensus regarding a given clinical protocol or practice considering all other clinical  
 39 characteristics noted above.

1 (3) Safe/low risk:

2 A safe clinical practice is one that has a known favorable diagnostic or therapeutic  
 3 outcome/value; does not place the patient at high risk of direct harm when properly  
 4 applied; does not result in a potential delay of implementation of a different but  
 5 established or proven diagnostic or therapeutic procedure; and has a benefit:risk ratio  
 6 that strongly favors benefit.

7  
 8 ASH defines a procedure as having a favorable benefit:risk ratio if:

- 9 • Standards exist to define the appropriate and reproducible application of the  
 10 procedure; and
- 11 • Training of practitioners is adequate to ensure competency; and
- 12 • There exists a third party review system to evaluate the competency of the  
 13 practitioner; and
- 14 • The procedure can be measured and, when compared to current known  
 15 procedures, is shown to be at least as safe or safer; and
- 16 • There are scientifically valid, published data to indicate that the benefit:risk  
 17 ratio of the procedure favors benefit over risk; or
- 18 • There are no scientifically valid, published data to indicate that the benefit:risk  
 19 ratio of the procedure favors risk over benefit.

20  
 21 (4) Clinical evidence:

22 Clinical evidence is diagnostic evidence and/or therapeutic functional outcome  
 23 evidence determined to be valid and reliable during the clinical assessment and the  
 24 treatment plan/program. This evidence validates diagnostic methods and determines  
 25 the efficacy of the treatment plan/program.

26  
 27 A treatment or procedure, a device, or a biological product may be determined by ASH to  
 28 be experimental or investigational if it is determined by a peer consensus review  
 29 committee that:

- 30 (1) It is under study to determine its maximum tolerated dose, its toxicity, its safety,  
 31 its efficacy, or its efficacy as compared with the currently accepted professional  
 32 standard means of treatment or diagnosis; or
- 33 (2) No credible scientific evidence exists regarding the device or biological product  
 34 or medical treatment or procedure; or
- 35 (3) Credible scientific evidence shows that the consensus of opinion among experts  
 36 regarding the device or biological product or medical treatment or procedure is  
 37 that further studies or clinical trials are necessary to determine its maximum  
 38 tolerated dose, its toxicity, its safety, its efficacy, or its efficacy as compared with  
 39 the currently accepted professional standard means of treatment or diagnosis; or
- 40 (4) Consensus of opinion of the ASH EEC and subsequent recommendation of ASH  
 41 clinical committees regarding the device or biological product or medical  
 42 treatment or procedure is that current scientific evidence has not shown it to be

1 safe, scientifically plausible, or effective. See policy Medical Necessity Definition  
2 - UM 8 – S for more information.

### 3 4 **Clinical Criteria Summary**

5 Clinical practices delivered by a practitioner or performed in the care of a member must  
6 be defined within professionally recognized standards of practice as reflected in ASH  
7 practice parameters and review criteria. This perspective recognizes that some health care  
8 practitioners deliver health care services that are within their scope of practice, but do not  
9 meet the practice parameters defined in this document. ASH recognizes that its practice  
10 parameters and review criteria represent a peer-reviewed, evidence-based optimal  
11 delivery model of professional practices within the health care disciplines.

### 12 13 **Clinical Decision-Making**

14 Practice parameters and review criteria for clinical decision-making are designed to  
15 determine whether:

- 16 • The practitioner’s credentials (education, training, license/registration/certification,  
17 malpractice coverage and history) are appropriate for their discipline and regulatory  
18 requirements;
- 19 • The clinical diagnostic and/or treatment practices potentially available to a member  
20 meet ASH standards, criteria, and requirements;
- 21 • The outcome of a given service occurred because the practitioner was or was not  
22 practicing within professionally recognized standards of practice;
- 23 • The services provided are medically necessary and/or clinically appropriate, delivered  
24 in accordance with professionally recognized standards of practice, and are allowed in  
25 the member’s contract; and
- 26 • A practitioner is willing to improve his/her practices where it was determined that a  
27 professional practice was not performed in accordance with ASH criteria.

### 28 29 **Clinical Services – Case Evaluation**

30 A key component of ASH benefit administration programs is its Clinical Services  
31 Program (CS Program). This is a peer review program that evaluates whether covered  
32 services are medically necessary. ASH utilizes licensed, credentialed peer clinical quality  
33 evaluators to review clinical documentation submitted for medical necessity review based  
34 upon the review criteria described in this document.

### 35 36 **Clinical Services Program**

37 ASH does not set fixed condition-specific treatment frequency or duration limitations.  
38 Each case is reviewed by considering pertinent clinical documentation submitted and  
39 understanding that similar case presentations should be handled in similar fashion with  
40 reasonably consistent results. For a given diagnosis, the effect of variability in general  
41 health status (age, gender, past medical history, psychosocial factors, and presence of co-

1 morbid conditions) makes the use of diagnosis-specific treatment tracks inherently  
 2 untenable.

3  
 4 ASH clinical quality evaluators are available by telephone to respond to practitioners'  
 5 questions or inquiries regarding the clinical services program or a specific issue related  
 6 to a case.

7  
 8 The goals of the clinical decision-making processes, which occur at both the practitioner-  
 9 member interface and the practitioner-ASH interface, are to approve within the member's  
 10 benefit program, clinical services necessary to restore the member's functional health  
 11 status, as clinically appropriate, or stabilize a chronic condition for which complete  
 12 resolution is not possible.

13  
 14 The initial encounter and subsequent clinical encounters between practitioner and  
 15 member have the purpose of assessing the member's health condition and delivering a  
 16 treatment care plan/program that addresses the clinical needs of the member based on the  
 17 results of those assessments. It is the responsibility of the ASH practitioner to document  
 18 the medical necessity of all treatment/services requested/provided. It is the responsibility  
 19 of the peer review ASH clinical quality evaluators to evaluate the documentation  
 20 submitted by the practitioner in accordance with their understanding of professionally  
 21 recognized standards of practice parameters and review criteria adopted by ASH.

22  
 23 ASH clinical quality evaluators have the responsibility to evaluate submitted  
 24 treatment/services for medically necessary and covered clinical conditions and/or care.  
 25 The clinical quality evaluators evaluate the clinical data supplied by the practitioner in  
 26 order to determine whether the initiation or continuation of care has been documented as  
 27 necessary. In many cases, the clinical documentation supplied provides sufficient  
 28 information to establish the need to initiate care, but the member's long term response to  
 29 the care cannot be predicted. In these circumstances, the clinical quality evaluator will  
 30 approve the initiation of the practitioner's proposed treatment plan/program. Approval of  
 31 continued care may require submission of additional information at various points within  
 32 the treatment plan/program. In those cases where the member has been approved for a  
 33 course of treatment and more treatment is requested by the practitioner, the decision to  
 34 approve additional treatment will be based on documentation submitted to support the  
 35 efficacy of further care, including:

- 36 • The member has made clinically significant progress under the initial treatment  
 37 plan/program. Clinically significant progress may be documented based on  
 38 completion of a reliable and valid outcome tool. Actual significance requires  
 39 correlation with the overall clinical presentation, including updated subjective and  
 40 objective examination findings.
- 41 • Additional clinically significant progress can be reasonably expected by  
 42 continued treatment;

- 1       • The member has not reached MTB or MMI; and  
2       • There is no indication that immediate care/evaluation is required by other health  
3       care professionals.  
4

5       It is appropriate not to approve ongoing services if the member’s condition is no longer  
6       improving despite the services being rendered by the treating practitioner. These  
7       procedures allow the member to receive appropriate care but take into account the  
8       variable responses that a member may have to the clinical intervention.